TITLE

Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer

AUTHOR(S)
King, M T; Viney, R; Smith, D P; Hossain, I; Street, D; Savage, E; Fowler, S; Berry, M P; Stockler, M; Cozzi, P; Stricker, P; Ward, J; Armstrong, B K
PUB. DATE
February 2012
SOURCE
British Journal of Cancer;2/14/2012, Vol. 106 Issue 4, p638
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background:Men diagnosed with localised prostate cancer (LPC) face difficult choices between treatment options that can cause persistent problems with sexual, urinary and bowel function. Controlled trial evidence about the survival benefits of the full range of treatment alternatives is limited, and patients' views on the survival gains that might justify these problems have not been quantified.Methods:A discrete choice experiment (DCE) was administered in a random subsample (n=357, stratified by treatment) of a population-based sample (n=1381) of men, recurrence-free 3 years after diagnosis of LPC, and 65 age-matched controls (without prostate cancer). Survival gains needed to justify persistent problems were estimated by substituting side effect and survival parameters from the DCE into an equation for compensating variation (adapted from welfare economics).Results:Median (2.5, 97.5 centiles) survival benefits needed to justify severe erectile dysfunction and severe loss of libido were 4.0 (3.4, 4.6) and 5.0 (4.9, 5.2) months. These problems were common, particularly after androgen deprivation therapy (ADT): 40 and 41% overall (n=1381) and 88 and 78% in the ADT group (n=33). Urinary leakage (most prevalent after radical prostatectomy (n=839, mild 41%, severe 18%)) needed 4.2 (4.1, 4.3) and 27.7 (26.9, 28.5) months survival benefit, respectively. Mild bowel problems (most prevalent (30%) after external beam radiotherapy (n=106)) needed 6.2 (6.1, 6.4) months survival benefit.Conclusion:Emerging evidence about survival benefits can be assessed against these patient-based benchmarks. Considerable variation in trade-offs among individuals underlines the need to inform patients of long-term consequences and incorporate patient preferences into treatment decisions.
ACCESSION #
71719393

 

Related Articles

  • Clinically relevant fatigue in recurrence-free prostate cancer survivors. Storey, D. J.; McLaren, D. B.; Atkinson, M. A.; Butcher, I.; Liggatt, S.; O’Dea, R.; Smyth, J. F.; Sharpe, M. // Annals of Oncology;Jan2012, Vol. 23 Issue 1, p65 

    Background: Little is known about the prevalence and associations of clinically relevant fatigue (CRF) in recurrence-free prostate cancer survivors.Patients and methods: Four hundred and sixteen recurrence-free prostate cancer survivors who were >1 year post-radiotherapy or radical prostatectomy...

  • Management of High-Risk Localized Prostate Cancer. Marciscano, Ariel E.; Hardee, Matthew E.; Sanfilippo, Nicholas // Advances in Urology;2012, p1 

    Traditionally, patients with high-risk localized prostate cancer have been an extremely challenging group to manage due to a significant likelihood of treatment failure and prostate cancer-specific mortality (PCSM). The results of multiple large, prospective, randomized trials have demonstrated...

  • Helical intensity-modulated Radiotherapy of the Pelvic Lymph Nodes with Integrated Boost to the Prostate Bed - Initial Results of the PLATIN 3 Trial. Katayama, Sonja; Habl, Gregor; Kessel, Kerstin; Edler, Lutz; Debus, Juergen; Herfarth, Klaus; Sterzing, Florian // BMC Cancer;2014, Vol. 14 Issue 1, p1 

    Background Adjuvant and salvage radiotherapy of the prostate bed are established treatment options for prostate cancer. While the benefit of an additional radiotherapy of the pelvic lymph nodes is still under debate, the PLATIN 3 prospective phase II clinical trial was initiated to substantiate...

  • Concern for overtreatment using the AUA/ASTRO guideline on adjuvant radiotherapy after radical prostatectomy. Jung Hun Kang; Yun-Sok Ha; Sung Kim; Jihyeong Yu; Patel, Neal; Parihar, Jaspreet S.; Salmasi, Amirali Hassanzadeh; Wun-Jae Kim; Isaac Yi Kim // BMC Urology;2014, Vol. 14 Issue 1, p1 

    Background Recently, three prospective randomized trials have shown that adjuvant radiotherapy (ART) after radical prostatectomy for the patients with pT3 and/or positive margins improves biochemical progression-free survival and local recurrence free survival. But, the optimal management of...

  • PROSTATE CANCER.  // Current Medical Literature: Urology;2005, Vol. 11 Issue 4, p93 

    This article discusses research being done prostate cancer. The study by S. J. Freedland et al dealt with the risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. The study by M. Bolla et al focused on randomized controlled clinical trial on...

  • Extended Salvage Pelvic Lymph Node Dissection in Patients with Recurrent Prostate Cancer. Osmonov, Daniar K.; Aksenov, Alexey V.; Boller, Annkathrin; Kalz, Almut; Heimann, Diana; Janssen, Isa; Jünemann, Klaus-Peter // Advances in Urology;2014, p1 

    Background. Treatment of patients with a biochemical recurrence (BCR) of prostate cancer (PCa) is generally difficult and without valid treatment options. Since 2004 we have been developing therapeutic possibilities for these patients. Methods. We retrospectively analyzed a cohort of 41 patients...

  • Value of bimodal F-choline-PET/MRI and trimodal F-choline-PET/MRI/TRUS for the assessment of prostate cancer recurrence after radiation therapy and radical prostatectomy. Paparo, Francesco; Piccardo, Arnoldo; Bacigalupo, Lorenzo; Romagnoli, Andrea; Piccazzo, Riccardo; Monticone, Michela; Cevasco, Luca; Campodonico, Fabio; Conzi, Giuseppe; Carmignani, Giorgio; Rollandi, Gian // Abdominal Imaging;Aug2015, Vol. 40 Issue 6, p1772 

    Between 27% and 53% of all patients who undergo radical prostatectomy (RP) or radiation therapy (RT) as the first-line treatment of prostate cancer (PCa) develop a biochemical recurrence. Imaging plays a pivotal role in restaging by helping to distinguish between local relapse and metastatic...

  • Radiotherapy for Oligometastases and Oligo-Recurrence of Bone in Prostate Cancer. Tabata, Ken-ichi; Niibe, Yuzuru; Satoh, Takefumi; Tsumura, Hideyasuq; Ikeda, Masaomi; Minamida, Satoru; Fujita, Tetsuo; Ishii, Daisuke; Iwamura, Masatsugu; Hayakawa, Kazushige; Baba, Shiro // Pulmonary Medicine;2012, p1 

    Purpose. To retrospectively evaluate the clinical significance of radiotherapy for oligometastases of bone in prostate cancer (PCa). Methods and Materials. Between 2003 and 2008, 35 PCa patients with oligometastases of bone were treated with radiotherapy. Results. The median radiotherapy dose...

  • Early Salvage Radiotherapy Yields Excellent Outcomes.  // Renal & Urology News;Jan2014, Vol. 13 Issue 1, p9 

    The article discusses the study led by Alberto Briganti Vita Salute San Raffaele University in Milan, Italy, which found the control of cancer following early salvage radiotherapy for biochemical recurrence of prostate cancer.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics